Table 4 |
|||
|
Incidence and type of serious adverse events |
|||
|
Variable |
Placebo group (n = 29) |
Selenium group (n = 31) |
P value |
|
|
|||
|
At least one serious adverse event |
18 (62) |
25 (81) |
0.111 |
|
Type of event |
|||
|
Respiratory failure |
1 (3) |
5 (16) |
0.196 |
|
Cardiac failure |
1 (3) |
1 (3) |
1.000 |
|
Renal failure |
1 (3) |
0 (0) |
0.483 |
|
Ischaemic event |
6 (21) |
2 (7) |
0.134 |
|
Intracranial haemorrhage |
1 (3) |
1 (3) |
1.000 |
|
Refractory shock |
6 (21) |
5 (16) |
0.648 |
|
Multiorgan failure |
4 (14) |
10 (32) |
0.091 |
|
Superinfection |
2 (7) |
1 (3) |
0.606 |
|
Othersa |
0 (0) |
2 (7) |
0.492 |
|
|
|||
|
Data presented as n (%). aIncludes one thrombocytopenia and one radial artery pseudoaneurysm. |
|||
|
Forceville et al. Critical Care 2007 11:R73 doi:10.1186/cc5960 |
|||
